Intervacc Stock

Intervacc EBIT

The EBIT of Intervacc (IVACC.ST) as of Aug 9, 2026 is -84.86 M SEK. In the previous year, EBIT was -77.28 M SEK — a change of 9.81% (lower).

EBIT

-84.86 MSEK

YoY

9.81%

Last updated:

In 2026, Intervacc's EBIT was -84.86 M SEK, a 9.81% increase from the -77.28 M SEK EBIT recorded in the previous year.

The Intervacc EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M SEK)
Date
EBIT (M SEK)
Jan 1, 2023
-93.58 base
Jan 1, 2024
-77.28 base
Jan 1, 2025
-84.86 base
Jan 1, 2026 (e)
-17.70 base
Jan 1, 2027 (e)
-30.05 base
Jan 1, 2028 (e)
-121.00 base
Jan 1, 2029 (e)
-166.00 base
Jan 1, 2030 (e)
-291.30 base
YEAREBIT (M SEK)
2030 est -291.30
2029 est -166.00
2028 est -121.00
2027 est -30.05
2026 est -17.70
2025 -84.86
2024 -77.28
2023 -93.58
2022 -64.41
2021 -29.39
2020 -25.68
2019 -27.85
2018 -30.92
2017 -13.67
2016 -7.40
2015 2.08
2014 10.11
2013 -2.45
Access this data via the Eulerpool API

Intervacc Revenue

Intervacc Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
8.02 M SEK
-93.58 M SEK
-102.85 M SEK
Jan 1, 2024
11.79 M SEK
-77.28 M SEK
-75.52 M SEK
Jan 1, 2025
20.09 M SEK
-84.86 M SEK
-80.82 M SEK
Jan 1, 2026 (e)
17.70 M SEK
-17.70 M SEK
-62.45 M SEK
Jan 1, 2027 (e)
30.05 M SEK
-30.05 M SEK
-65.42 M SEK
Jan 1, 2028 (e)
121.00 M SEK
-121.00 M SEK
-49.07 M SEK
Jan 1, 2029 (e)
166.00 M SEK
-166.00 M SEK
0.00 SEK
Jan 1, 2030 (e)
291.30 M SEK
-291.30 M SEK
0.00 SEK

Intervacc Margins

Intervacc stock margins

The Intervacc margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Intervacc. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Intervacc.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
-172.25 %
-1,167.55 %
-1,283.24 %
Jan 1, 2024
-29.92 %
-655.61 %
-640.66 %
Jan 1, 2025
-335.60 %
-422.45 %
-402.32 %
Jan 1, 2026 (e)
-335.60 %
-100.00 %
-352.81 %
Jan 1, 2027 (e)
-335.60 %
-100.00 %
-217.71 %
Jan 1, 2028 (e)
-335.60 %
-100.00 %
-40.55 %
Jan 1, 2029 (e)
-335.60 %
-100.00 %
0.00 %
Jan 1, 2030 (e)
-335.60 %
-100.00 %
0.00 %

Intervacc Stock analysis

What does Intervacc do? Intervacc AB is a Swedish biotechnology company specializing in the development and production of vaccines for animals. The company was founded in 2003 by researchers who wanted to develop an alternative to traditional vaccines made from weakened or killed pathogens. Intervacc AB's business model is based on the development of subunit vaccines, which consist of the key proteins of the pathogens and allow targeted immune responses in animals. Subunit vaccines are safe and effective, offering many advantages over traditional vaccines by minimizing the risk of side effects and allowing targeted combat against specific pathogens. The different divisions at Intervacc AB include the development of vaccines for animals such as horses, pigs, chickens, and cattle. The company also has plans to develop vaccines for other animal species in the future, such as dogs and cats. Among the products offered by Intervacc AB are various vaccines in different stages of development. One of its key products is Equilis StrepE, used for the preventive treatment of myopathy in horses. The vaccination is already being used in many countries and is an important part of horse healthcare. Another product is Porcilis AR-T DF, used to vaccinate pigs against atrophic rhinitis (AR). Intervacc AB is also developing new products, such as a vaccine for the prevention of Lyme borreliosis in horses and a vaccine against bacterial pneumonia in calves. The company is constantly searching for new vaccines to improve animal health and welfare, and several patents have been filed. The history of Intervacc AB is marked by ambitious goals and scientific breakthroughs. In 2004, the first steps were taken towards developing subunit vaccines for horse diseases. In 2007, the company began clinical trials of Equilis StrepE, which was later acquired by Boehringer Ingelheim Animal Health in 2016. In 2011, Intervacc AB developed Porcilis AR-T DF, a vaccine against atrophic rhinitis in pigs. Since then, the company has expanded its research and development into various areas and formed numerous partnerships. Intervacc AB utilizes cutting-edge technologies and has an experienced team of scientists and professionals who collaborate closely to develop and test new vaccines. The company is based in Uppsala, Sweden, and has state-of-the-art laboratory and production facilities. Overall, Intervacc AB has established itself as an innovative company specializing in the development of safe and effective vaccines for animals. Its products and services contribute to improving the health and well-being of animals and making animal husbandry more sustainable and efficient. Intervacc is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Intervacc's EBIT

Intervacc's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Intervacc's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Intervacc's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Intervacc’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Intervacc stock

EBIT of Intervacc is -84.86 M SEK in 2026.

EBIT of Intervacc changed from -77.28 M SEK to -84.86 M SEK, representing a 9.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Intervacc since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Intervacc historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Intervacc

All Key Metrics — Intervacc